20 commercial payer policies list J9329. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
20 policies from 17 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tislelizumab-jsgr (Tevimbra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Tislelizumab-jsgr (Tevimbra) | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tislelizumab-jsgr (Tevimbra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Tislelizumab-jsgr (Tevimbra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tevimbra (tislelizumab-jsgr) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Tevimbra (tislelizumab-jsgr) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tislelizumab-jsgr (e.g., Tevimbra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| TEVIMBRA | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tislelizumab-jsgr (Tevimbra) | Oct 31, 2024 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tislelizumab-jsgr (Tevimbra); CP.PHAR.687 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List | Not recorded | Prior auth required |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Tevimbra (tislelizumab) (PG210, Ver. 3) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medication Clinical Coverage | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medication Clinical Coverage | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J9329 |
|---|---|---|
| Oncology Medication Clinical Coverage | Apr 1, 2026 | Covered |